Characteristics and Outcomes of Patients With Dedifferentiated Liposarcoma in a US Community Setting
Real-world data from sarcoma patients show most still receive older chemotherapy; newer targeted drugs tested in upcoming trials could improve survival.
This retrospective EHR analysis of 123 DDLPS patients in US community oncology settings revealed that biomarker testing is increasing (MDM2 78%) but treatment remains predominantly anthracycline-based with poor metastatic outcomes (rwOS 11.7 months), highlighting the unmet therapeutic need in this rare soft-tissue sarcoma. The findings provide real-world benchmarks for future trials of MDM2- and CDK4-targeted therapies.
What the study was
- Study design
- Retrospective observational study (EHR-based)
- Population
- Patients with dedifferentiated liposarcoma (DDLPS) in US Oncology Network community settings, 2008-2023
- Sample size
- 123
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cancer Medicine
Why it surfaced
DDLPS is rare (orphan), has high unmet need, and this is the largest US community-setting real-world dataset available. MDM2/CDK4 biomarker testing rates contextualized against survival benchmarks is pipeline-relevant for targeted therapy development.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.